X
    學術可視化工作室RC   登錄   提交文稿
學術英文編修

Therapeutic Advances in Medical Oncology

期刊標題檢索 THER ADV MED ON 最新評論: Administrative checks complete Initial checks have been completed and ... (2024-01-15)


期刊名稱:   ISSN:   主題領域:   影響因子範圍: -
索引:   類別:   開放訪問:   排序方式:

[Therapeutic Advances in Medical Oncology]您好,您是該頁面的第 41589 位訪客。

期刊簡介
期刊名稱Therapeutic Advances in Medical Oncology Therapeutic Advances in Medical Oncology
LetPub Score
7.1
50 ratings
Rate

Reputation
8.1

Influence
6.4

Speed
6.9

期刊簡稱THER ADV MED ONCOL
ISSN1758-8340
E-ISSN1758-8359
h-index34
CiteScore
CiteScoreSJRSNIPCiteScore Rank
8.201.5291.009
Subject fieldQuartilesRankPercentile
Category: Medicine
Subcategory: Oncology
Q178 / 404

自引率 (2023-2024)2.30%自引率趨勢
掲載範囲
Therapeutic Advances in Medical Oncology delivers the highest quality peer-reviewed original research articles, reviews, and scholarly comment on pioneering efforts and innovative studies in the medical treatment of cancer. The journal has a strong clinical and pharmacological focus and is aimed at an international audience of clinicians and researchers in medical oncology, providing an online forum for rapid dissemination of recent research and perspectives in this area.

The journal is dedicated to publishing clinical research. We do not publish preclinical research, including basic laboratory research and animal studies.

Review articles include expert opinion/perspective reviews (including single-drug and drug class reviews), narrative reviews and therapeutic area reviews. Systematic reviews, meta-analyses, postmarketing and health economic and pharmacoeconomic reviews are also welcomed. The appropriate EQUATOR Network reporting guidelines should be followed (e.g. CONSORT for randomized, controlled trials and PRISMA for systematic reviews/meta-analyses). Therapeutic Advances in Medical Oncology conforms to the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first patient enrolment as a condition of consideration for publication. The trial registry name and URL, and registration number must be included at the end of the abstract.

The journal adheres to a blind review process in which the reviewer’s name is routinely withheld from the author unless the reviewer requests a preference for their identity to be revealed. Manuscripts are reviewed by at least two referees; and Online First publication is usually within 3 weeks of Acceptance.
官方網站https://journals.sagepub.com/home/tam
在線稿件提交https://mc.manuscriptcentral.com/tao
開放訪問Yes
出版商SAGE Publications Inc.
主題領域ONCOLOGY
出版國/地區ENGLAND
發行頻率継続刊行
創刊年2009
每年文章數194每年文章數趨勢
黃金OA百分比89.69%
OA Related Info
APC: Yes( USD2800; )
APC waiver:Check Notes
Other charges: No
Keywords: oncology、cancer
Useful LinksAims & ScopeAuthor InstructionsEditorial BoardAnonymous peer review
Web of Science 四分位
2023-2024
WOS Quartile: Q2

CategoryEditionJIF QuartileJIF RankingJIF Percentage
ONCOLOGYSCIEQ288/322
索引 (SCI or SCIE)Science Citation Index Expanded
鏈接到PubMed Central (PMC)https://www.ncbi.nlm.nih.gov/nlmcatalog?term=1758-8340%5BISSN%5D
平均審稿時間 *來自出版商的數據:
來自作者的數據: 15 Weeks
競爭力 *來自作者的數據:
參考鏈接
相關期刊 【Therapeutic Advances in Medical Oncology】CiteScore趨勢
自引率趨勢 每年文章數趨勢
作者評論
*所有的審稿過程指標,如接受率和審稿速度,僅限於用戶提交的稿件。因此,這些指標可能無法準確反映期刊的競爭力或速度。
  • 同一學科的期刊
  • CiteScore趨勢
  • 自引率趨勢
  • 每年文章數趨勢
  •  
    學科內的可信期刊 影響因子
    CA-A CANCER JOURNAL FOR CLINICIANSH-index: 144

    CiteScore: 873.20
    NATURE REVIEWS DRUG DISCOVERYH-index: 289

    CiteScore: 137.40
    LANCETH-index: 700

    CiteScore: 148.10
    NEW ENGLAND JOURNAL OF MEDICINEH-index: 933

    CiteScore: 145.40
    Nature Reviews Clinical OncologyH-index: 127

    CiteScore: 99.40
    Nature Reviews Disease PrimersH-index: 48

    CiteScore: 76.70
    NATURE REVIEWS CANCERH-index: 396

    CiteScore: 111.90
    NATURE REVIEWS IMMUNOLOGYH-index: 351

    CiteScore: 93.40
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATIONH-index: 622

    CiteScore: 48.20
    World PsychiatryH-index: 70

    CiteScore: 64.10
    學科內最受檢索的期刊 頁面查看次數
    MEDICINE640767
    BIOMATERIALS569978
    BIOMEDICINE & PHARMACOTHERAPY498334
    Frontiers in Pharmacology486668
    JOURNAL OF ETHNOPHARMACOLOGY477098
    Journal of Materials Chemistry B476057
    Frontiers in Immunology457894
    COLLOIDS AND SURFACES B-BIOINTERFACES419218
    COMPUTERS IN BIOLOGY AND MEDICINE416322
    Frontiers in Oncology413401
  •  

    Therapeutic Advances in Medical Oncology Therapeutic Advances in Medical Oncology
    明年預測:
    穩步上升 無變化 逐步下降  刷新
  •  

     
  •  

     


首頁    上一頁    1    2    3    4    下一頁    末頁  (頁
/4)
  [Therapeutic Advances in Medical Oncology] 的評論撰寫評論
作者: 水月子武


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-01-15 12:07:12 評論於
Administrative checks complete
Initial checks have been completed and Editor assignment is being determined. This status has been maintained for 11 days, what does this mean?
(0) 讚! | 水月子武

作者: 水月子武


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-01-09 12:07:20 評論於
May I ask for a timeline?
(0) 讚! | 水月子武

作者: 水月子武


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-01-04 23:48:23 評論於
May I ask how the progress is going?
(0) 讚! | 水月子武

作者: 水月子武


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-01-04 22:00:29 評論於
May I ask for the timeline?
(0) 讚! | 水月子武

作者: 水月子武


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-01-04 19:04:53 評論於
How is your progress coming along?
(0) 讚! | 水月子武

作者: 东海弘光


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-11-07 12:03:30 評論於
The journal recommended by my senior brother is said to have good article quality, but the number of articles published in China is relatively low. I guess it may be a bit strict. I am preparing to submit an article, mainly because I don't have to worry about it being blacklisted
(0) 讚! | 东海弘光

作者: 深渊诗语


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-11-06 15:02:04 評論於
I am also still waiting for the results
(0) 讚! | 深渊诗语

作者: 形意炜曦


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-11-05 11:07:06 評論於
The review process was very smooth, and the reviewers' comments were very professional, significantly improving the quality of the article. The review speed was fast and the editor was friendly, which was completely different from the British style. However, the innovation and linguistic level of the article still need to be improved
(0) 讚! | 形意炜曦

作者: 极乐慕山


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-11-01 12:02:32 評論於
The initial review and revision process took one and a half months, and the total time until acceptance confirmation was three months, which went very smoothly. I think this journal is good, with a high acceptance rate for submissions, and is worth considering!
(0) 讚! | 极乐慕山

作者: 凤凰院正平


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-10-16 17:26:16 評論於
Please translate the following paragraph into English and Japanese, and title them as ":" and ":"
(0) 讚! | 凤凰院正平

作者: 岭南易丹


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-09-28 20:55:08 評論於
Hey, how did your article turn out in the end? Is it under review? After receiving the reviewer invitation, mine didn't go to under review and went straight back to editor assessment. Does that mean it's not going to make it?
(0) 讚! | 岭南易丹

作者: 岭南易丹


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-09-28 18:13:26 評論於
Hey, how did your article turn out in the end? Is it under review? Mine went back to editor assessment after reviewer invitation without going through under review, does that mean it's not going well?
(0) 讚! | 岭南易丹

作者: 岭南易丹


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-09-28 12:17:21 評論於
Hello, may I ask if there is a situation where the status changes from "reviewer invitation and response being received" to "The Editor is assessing your submission for peer review"? There is no "under review" status in between, is this a bad sign? Or does it mean that reviewers have not been invited?
(0) 讚! | 岭南易丹

作者: yayacee


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-09-28 11:12:00 評論於
Dear, how is the status of your article now? Is it under review? Mine also changed back to editor assessment directly after reviewer invitation, is it going to be rejected?
(0) 讚! | yayacee

作者: 五虎青亦


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-09-11 16:44:10 評論於
Hello, I would like to ask about the final outcome of your submission
(0) 讚! | 五虎青亦

作者: Nick Xie


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-07-29 18:41:08 評論於
Is it normal to have Editor assessment for two months even though I have already submitted? There were intermittent Reviewer invitations in between, and then it returned to Editor assessment again.
(0) 讚! | Nick Xie

作者: 景焕小姐姐


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-05-05 14:59:52 評論於
Review Speed: 12.0 | Submission Acceptance Rate: 50.0 
Emphasized Research Direction: Tumor 
Clinical Treatment Experience Sharing: It took 9 months from submission to final acceptance, which is a bit long. The delay might be due to the impact of the pandemic. This is just a sharing of personal experience
(0) 讚! | 景焕小姐姐

作者: 水桥昆锐


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-04-20 18:56:38 評論於
Bro, I'm facing a similar situation now. I wanted to ask how your article ended
(0) 讚! | 水桥昆锐

作者: 水桥昆锐


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-04-20 17:34:22 評論於
Bro, I also encountered this situation, just wondering how it turned out in the end
(0) 讚! | 水桥昆锐

作者: 谷玉mio


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-01-16 12:11:35 評論於
May I ask what is the final result for you? I also received the "The Editor is assessing your submission for peer review," after 1 and a half weeks from receiving the reviewer invitation and response. Does this mean it will be rejected?
(0) 讚! | 谷玉mio

作者: 谷玉mio


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-01-16 08:16:05 評論於
Hey, I'm in the same situation. How is your paper going?
(0) 讚! | 谷玉mio

作者: 水月悦洋


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-11-11 21:43:38 評論於
It has been almost two months for me, and I have been constantly looking for reviewers
(0) 讚! | 水月悦洋

作者: 水月悦洋


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-10-27 16:35:00 評論於
How are you feeling now? I also keep going back to this state
(0) 讚! | 水月悦洋

作者: 北国爱宝


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-10-09 08:40:24 評論於
Can you translate the following paragraph into English and Japanese, and use ":" and ":" as titles?
(0) 讚! | 北国爱宝

作者: Woodrow Mike


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-08-21 10:48:49 評論於
It's been almost 2 months since submission, but there has been no response yet. Is everyone this slow?
(0) 讚! | Woodrow Mike

首頁    上一頁    1    2    3    4    下一頁    末頁  (頁
/4)

開始撰寫 [Therapeutic Advances in Medical Oncology] 的評論:





Contact us

Contact us  

Your name*

Your email*

Your message*

Please fill in all fields and provide a valid email.

Security Code*